Clinical trials: HIV Positive
Non-tuberculous Mycobacterial Diseases, Tuberculosis
Safety And Efficacy Of Rifabutin In HIV Patients
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Conditions
- Non-tuberculous Mycobacterial Diseases, Tuberculosis, Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
- Trial name
- NCT00810446
- Testing
- rifabutin
- Volunteers
- 72 people
- Sponsor
- Pfizer
HIV Infections, Pneumococcal Infections
A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants
To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subjects.
- Trial name
- NCT00000829
- Testing
- Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent
- Where
- 33 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Positive
Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People
The health of the immune system in HIV infected people is currently determined from a blood test measuring the number of cluster of differentiation 4 (CD4) T lymphocytes. These cells play a critical role in an immune response.
- Trial name
- QFM (NCT01904201)
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- QIAGEN Gaithersburg, Inc
Visceral Leishmaniasis, Human African Trypanosomiasis
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
Tropical fevers have been a diagnostic challenge from the antiquity. Nowadays, despite the availability of good diagnostic capacities, undifferentiated febrile illnesses continue to be a thorny problem for travel physicians.
- Conditions
- Visceral Leishmaniasis, Human African Trypanosomiasis, Enteric Fever, Melioidosis
- Trial name
- NCT01766830
- Testing
- rk28 ICT, IT LEISH (rK39), Immunochromatographic HAT test
- Where
- 7 sites in Cambodia, Democratic Republic of the Congo and 2 more
- Volunteers
- 1,927 people
- Sponsor
- University Hospital, Geneva
HIV Infections
Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir
With the roll out of antiretroviral therapy (ARV) for HIV across sub-Saharan Africa an unprecedented number of people will be commencing lifelong therapy.
- Trial name
- NCT00619944
- Testing
- Lumefantrine - lopinavir/ritonavir drug interaction, Lumefantrine only arm
- Where
- Uganda
- Volunteers
- 32 people
- Sponsor
- Makerere University
Anus Neoplasms, HIV Infections
Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men
The purpose of this study is to assess if argon plasma coagulation (APC) is a safe and well tolerated treatment method for anal intraepithelial neoplasia (AIN) grade 2/3 in HIV-positive men having sex with men (MSM).
- Trial name
- NCT00428285
- Testing
- Argon Plasma Coagulation
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Hypercholesterolemia, HIV Infections
Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
This study involves comparing the effectiveness of treatments in HIV positive patients who may be predisposed to heart attack or stroke.
- Trial name
- NCT00908011
- Testing
- Ezetimibe, Rosuvastatin (standard care)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- University of British Columbia
HIV Infection
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
Despite overall declines in HIV incidence and mortality since ART scale-up in low and middle income countries, both have risen among youth.
- Trial name
- NCT02921516
- Testing
- N'ap Grandi, N'ap Grandi - A, Health Promotion - A
- Where
- Haiti
- Volunteers
- 278 people
- Sponsor
- Florida International University
HIV Infection
Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX
Purpose: The purpose of this study is to determine if a comprehensive intervention supporting seek-test-and-treat results in a significant reduction in the potential for HIV-infected prisoners to transmit their virus after…
- Trial name
- imPACT (NCT01629316)
- Testing
- Text reminders, counseling, and link coordination, Standard of care - control arm
- Where
- 2 sites in United States
- Volunteers
- 381 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections, Tuberculosis
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
Rifampin (RIF) is used for the treatment of tuberculosis (TB), an infectious disease that affects many people with HIV. RIF was shown to lower concentrations and decrease the effectiveness of some anti-HIV drugs, including the…
- Trial name
- NCT00096850
- Testing
- Atazanavir, Rifampin, Ritonavir
- Where
- 3 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment
The purpose of this study is to test the safety and effectiveness of a new non-nucleoside reverse transcriptase inhibitor (NNRTI), (+)-calanolide A, in HIV-positive patients who have never received anti-HIV treatment.
- Trial name
- NCT00002243
- Testing
- Calanolide A
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sarawak MediChem Pharmaceuticals
HIV Infections
Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors
The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination containing indinavir and ritonavir to HIV-positive patients who have failed previous treatment with protease inhibitors.
- Trial name
- NCT00002361
- Testing
- Indinavir sulfate, Ritonavir
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, Hepatitis C, Chronic
HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
This is an prospective open label pilot study conducted over 32 weeks. A total of 25 eligible participants who are infected with HCV and HIV will be recruited from 2 Canadian HIV Trials Network (CTN) sites (Ottawa Hospital…
- Trial name
- CTN289 (NCT02660905)
- Testing
- E/C/F/TAF;, Ledipasvir-Sofosbuvir
- Where
- 2 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Ottawa Hospital Research Institute
HIV Infections, Pneumococcal Infections
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who have not been previously immunized with a…
- Trial name
- NCT00962780
- Testing
- 13-valent Pneumococcal Conjugate Vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS), Blood draw
- Where
- 11 sites in Romania, South Africa
- Volunteers
- 303 people
- Sponsor
- Pfizer
HIV
Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth
Alcohol use among persons with HIV exacerbates health problems and accelerates HIV disease progression. Antiretroviral therapy (ART) is the single most important treatment for people living with HIV.
- Trial name
- NCT01969461
- Testing
- Motivational Enhancement Therapy (MET)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Wayne State University
HIV, Neurocognitive Disorders
Impact of Probiotics in HIV-positive Patients With Neurocognitive Disorders
The prevalence of HIV-associated neurocognitive disorders (Human Immunodeficiency Virus) remains high during the era of effective triple therapy.
- Trial name
- PROCOG (NCT04175223)
- Testing
- Vivomixx
- Where
- 3 sites in France
- Volunteers
- 32 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
HIV-1 Infection
Gene Transfer for HIV Using Autologous T Cells
This is a pilot study to determine the safety and feasibility of lentivirus-transduced T-cell immunotherapy in patients who have failed highly active anti-retrovirus therapy (HAART).
- Trial name
- Gene Transfer (NCT01153646)
- Testing
- pHIV7-shI-TAR-CCR5RZ treated CD4 cells
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- City of Hope Medical Center
Peri-Implantitis
Peri-implantitis in HIV-positive Patients
Objectives: This study aimed to assess the prevalence of peri-implantitis in human im-munodeficiency virus (HIV) -positive patients and the presence of a possible correlation between the immunological profile and serological…
- Trial name
- PERIHIV2 (NCT04829968)
- Testing
- gingival conditions control
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Università Vita-Salute San Raffaele
Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Background: Burkitt lymphoma/leukemia (BL) is highly treatable, but most of the standard therapies require multiple doses of intensive chemotherapy that may require long hospital stays and frequently have severe side effects.
- Conditions
- Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
- Trial name
- NCT01092182
- Testing
- EPOCH-R, EPOCH-RR
- Where
- 30 sites in United States
- Volunteers
- 194 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer
RATIONALE: Antiviral agents are drugs that act against viruses and may be an effective treatment for HIV. Peripheral stem cell transplantation or umbilical cord blood transplantation may be able to replace immune cells that were…
- Trial name
- NCT00003435
- Testing
- anti-thymocyte globulin, melphalan, antiviral therapy
- Where
- United States
- Sponsor
- Duke University